Literature DB >> 6300247

In vitro growth of B lymphocytes infiltrating human melanoma tissue by transformation with EBV: evidence for secretion of anti-melanoma antibodies by some transformed cells.

D B Watson, G F Burns, I R Mackay.   

Abstract

Epstein Barr virus was used to transform the B lymphocytes infiltrating metastatic tumor tissue from seven patients with melanoma. In this way it was possible to establish continuously growing B lymphoblastoid cell lines (LCL) derived from the tumor-infiltrating B lymphocytes from each of the seven patients. Antibody production of up to 50 micrograms/ml could be achieved by such cultures, and the lymphoblastoid cells could be cloned readily by limit dilution on a feeder layer of irradiated fetal fibroblasts. Preliminary analysis of the antibodies produced by lymphoblastoid cell lines established from tumors from two of the patients indicated that most were of IgM type and bound to a panel of melanoma cell target cells, as well as to some nonmelanoma tumor cell lines. Cloned LCL were produced from the tumor-infiltrating B cells from one of the patients, and of 100 such clones tested, 9% secreted antibody that bound to autologous tumor cells, and one of these clones produced antibody that appeared to be melanoma specific.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6300247

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Production of human monoclonal anti-basement membrane zone (BMZ) antibodies from a patient with bullous pemphigoid (BP) by Epstein-Barr virus transformation. Analyses of the heterogeneity of anti-BMZ antibodies in BP sera using them.

Authors:  T Sugi; T Hashimoto; T Hibi; T Nishikawa
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

2.  Cloned human cytotoxic T lymphocytes develop anomalous killer cell function.

Authors:  G F Burns; T Triglia; J A Werkmeister
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

3.  Cell-surface antigens of melanoma recognized by human monoclonal antibodies.

Authors:  H Yamaguchi; K Furukawa; S R Fortunato; P O Livingston; K O Lloyd; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

4.  Human IgG and IgM monoclonal antibodies against autologous melanoma produced by Epstein-Barr-virus-transformed B lymphocytes.

Authors:  J M Kirkwood; J E Robinson
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  TGF beta down-regulates TLiSA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells.

Authors:  B Jin; J L Scott; M A Vadas; G F Burns
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

Review 6.  Human monoclonal antibodies.

Authors:  S P Cole; B G Campling; T Atlaw; D Kozbor; J C Roder
Journal:  Mol Cell Biochem       Date:  1984-06       Impact factor: 3.396

Review 7.  Human monoclonal antibodies: methods of production and some aspects of their application in oncology.

Authors:  L Olsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

8.  TLiSA1, a human T lineage-specific activation antigen involved in the differentiation of cytotoxic T lymphocytes and anomalous killer cells from their precursors.

Authors:  G F Burns; T Triglia; J A Werkmeister; C G Begley; A W Boyd
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

9.  IgG4 subclass antibodies impair antitumor immunity in melanoma.

Authors:  Panagiotis Karagiannis; Amy E Gilbert; Debra H Josephs; Niwa Ali; Tihomir Dodev; Louise Saul; Isabel Correa; Luke Roberts; Emma Beddowes; Alexander Koers; Carl Hobbs; Silvia Ferreira; Jenny L C Geh; Ciaran Healy; Mark Harries; Katharine M Acland; Philip J Blower; Tracey Mitchell; David J Fear; James F Spicer; Katie E Lacy; Frank O Nestle; Sophia N Karagiannis
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.